BGNE vs. TEVA, BMRN, VTRS, SRPT, RDY, UTHR, GMAB, ALNY, CTLT, and ROIV
Should you be buying BeiGene stock or one of its competitors? The main competitors of BeiGene include Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
BeiGene (NASDAQ:BGNE) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations.
BeiGene presently has a consensus price target of $250.13, indicating a potential upside of 52.11%. Teva Pharmaceutical Industries has a consensus price target of $13.78, indicating a potential downside of 12.44%. Given BeiGene's stronger consensus rating and higher possible upside, research analysts clearly believe BeiGene is more favorable than Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries has higher revenue and earnings than BeiGene. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries received 769 more outperform votes than BeiGene when rated by MarketBeat users. However, 69.10% of users gave BeiGene an outperform vote while only 67.53% of users gave Teva Pharmaceutical Industries an outperform vote.
In the previous week, Teva Pharmaceutical Industries had 20 more articles in the media than BeiGene. MarketBeat recorded 26 mentions for Teva Pharmaceutical Industries and 6 mentions for BeiGene. BeiGene's average media sentiment score of 0.56 beat Teva Pharmaceutical Industries' score of 0.52 indicating that BeiGene is being referred to more favorably in the media.
48.6% of BeiGene shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 7.4% of BeiGene shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Teva Pharmaceutical Industries has a net margin of -3.33% compared to BeiGene's net margin of -35.86%. Teva Pharmaceutical Industries' return on equity of 34.90% beat BeiGene's return on equity.
BeiGene has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
Summary
Teva Pharmaceutical Industries beats BeiGene on 10 of the 18 factors compared between the two stocks.
Get BeiGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
